Results 121 to 130 of about 222,217 (297)
Frontiers in OncologyObjectiveThe combination of high-dose cyclophosphamide (HD-Cy) (3g/m2) plus granulocyte colony-stimulating factor (G-CSF) and on-demand plerixafor (PXF) has been considered an effective mobilization regimen of patients with multiple myeloma(MM). However,
Li-qiong Hou +7 more
doaj +1 more source
Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma.
, 1988 Recent improvements in survival of patients with Ewing's sarcoma have been made since the addition of cyclophosphamide-based adjuvant chemotherapy to primary surgery and radiation.
T J Stillwell, E O Burgert, R C Benson
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng +7 more
wiley +1 more source
Secondary acute myeloid leukemia arising early after cyclophosphamide treatment
, 2015 Background Acute myeloid leukemia (AML) can develop secondary to drug treatment. This phenomenon has been placed under the title "Therapy Related Acute Myeloid Leukemias and Myelodysplastic Syndromes" in the WHO classification of AML.
AKYÜREK, NALAN +4 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker +4 more
wiley +1 more source
Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review
British Journal of Clinical Pharmacology, EarlyView.Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti +9 more
wiley +1 more source
A theoretical study of H3PO4, nor-N-mustard, and cyclophosphamide
, 2014 Some physical and chemical properties of the cancerostat cyclophosphamide (generic name: ENDOXAN) and its basic constituents H3PO4 and nor-N-mustard have been calculated with the help of a modified CNDO/S-method.
Ulmer, Waldemar
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman +3 more
wiley +1 more source